36 results on '"Huey, Ryan W"'
Search Results
2. A randomized study evaluating tailoring of advanced/metastatic colorectal cancer (mCRC) therapy using circulating tumor DNA (ctDNA): TACT-D.
3. Immune checkpoint inhibitor-associated gastrointestinal adverse events in patients with colorectal cancer.
4. Time dependency for HPV ctDNA detection as a prognostic biomarker for anal cancer.
5. Clinical and pathological characteristics of cancer of unknown primary with renal profile using gene expression profiling (GEP)–based cancer classification.
6. A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy compared to synthetic control cohort: Results from the MD Anderson INTERCEPT program.
7. Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic Cancer
8. Leveraging the 21st Century Cures Act to Improve Cancer Care, Patient Engagement, and Data Collection
9. A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy: Results from the MD Anderson INTERCEPT Program.
10. Redefining the prognostic significance of RAS and BRAF V600E mutations on disease free survival in patients with colorectal cancer in the era of ct-DNA defined minimal residual disease: Results from the MD Anderson INTERCEPT Program.
11. Utility of gene expression–based cancer classification in diagnosis of malignant peritoneal mesothelioma (MPeM): Filling in the gaps in standard pathologic work-up for a rare cancer.
12. Natural history and patterns of progression for dMMR/MSI-H colorectal cancer treated with immune checkpoint blockade: A single center retrospective analysis.
13. INTERCEPT Program of circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) in colorectal cancer (CRC): Results from a prospective clinical cohort.
14. Abstract C084: iExplore: A phase I study of mesenchymal stem cell derived exosomes with KrasG12D siRNA for metastatic pancreas cancer patients harboring the KrasG12D mutation
15. Feasibility and Value of Genomic-Profiling in Cancer of Unknown Primary: Real-World Evidence from Prospective Profiling Study
16. Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers
17. Supplementary Data from Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary
18. Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait
19. Abstract B028: Changes in exosomal RNA expression associate with treatment response to BRAF + EGFR + PD-1 blockade in MSS, BRAFV600E colorectal cancer: A liquid biopsy approach
20. Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial
21. Implementation of a stereotactic body radiotherapy program for unresectable pancreatic cancer in an integrated community academic radiation oncology satellite network
22. Developing a Value Framework: Utilizing Administrative Data to Assess an Enhanced Care Initiative
23. Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials
24. Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary
25. Follicular dendritic cell sarcoma in the differential diagnosis of GATA3 positive tumors: A case report
26. Cancer of Unknown Primary Presenting as Bone-Predominant or Lymph Node-Only Disease: A Clinicopathologic Portrait
27. Abstract PO-208: Patient-reported out-of-pocket costs and financial toxicity during early- phase oncology clinical trials
28. CD28 expression redefines thymocyte development during the pre-T to DP transition
29. Mind the Gap: Precision Oncology and Its Potential to Widen Disparities
30. Molecular diagnostic classification for cancers of unknown primary (CUP): Post-testing diagnosis and treatment impact analysis from real-world claims data.
31. Cancer of unknown primary with gastrointestinal profiles: A distinct CUP subset.
32. HPV integration as a prognostic biomarker for metastatic anal cancer: A next-generation sequencing ctDNA-based approach.
33. Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer (CRC): Results from the MD Anderson INTERCEPT program.
34. Cancer chemotherapeutic agents as human teratogens
35. Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial.
36. Feasibility and value of genomic profiling in cancer of unknown primary: real-world evidence from prospective profiling study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.